TGFB1 and Hodgkins lymphoma: Early research using EBV-specific cytotoxic T-cell lymphocytes used for the treatment of EBV-positive Hodgkin disease show that modification through the expression of a dominant-negative TGFBR2 resisted the immunosuppressive effects of TGFB and enhanced cytotoxicity [132,133].